Antigen recognition and T-cell biology.
Despite the wealth of information that has been acquired regarding the way T cells recognize their targets, we are left with far more questions than answers regarding how to manipulate the immune response to better treat cancer patients. Clearly, most patients have a broad repertoire of T cells capable of recognizing their tumor cells. Despite the presence of these tumor reactive T cells and our ability to increase their frequency though vaccination or adoptive transfer, patients still progress. From the T cell side, defects in T cell signaling may account for much of our failure to achieve significant numbers of objective clinical responses. In spite of these negatives, the horizon does remain bright for T cell based immune therapy of cancer. The periodic objective clinical response tells us that immune therapy can work. Now that we know that cancer patients have the capacity to mount immune responses against their tumors, current and future investigations with agents which alter T cell function combined with vaccination or adoptive T cell transfer may help tip the balance towards effective immune therapies.
Nishimura
Michael I
MI
Department of Surgery, University of Chicago Medical Center, Chicago, IL 60637, USA.
Roszkowski
Jeffrey J
JJ
Moore
Tamson V
TV
Brasic
Natasha
N
McKee
Mark D
MD
Clay
Timothy M
TM
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D011948:Receptors, Antigen, T-Cell